These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10945372)

  • 21. Principles of signal detection in pharmacovigilance.
    Meyboom RH; Egberts AC; Edwards IR; Hekster YA; de Koning FH; Gribnau FW
    Drug Saf; 1997 Jun; 16(6):355-65. PubMed ID: 9241490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semantic distance-based creation of clusters of pharmacovigilance terms and their evaluation.
    Dupuch M; Grabar N
    J Biomed Inform; 2015 Apr; 54():174-85. PubMed ID: 25659451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
    Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
    Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.
    Jaquenoud Sirot E; van der Velden JW; Rentsch K; Eap CB; Baumann P
    Drug Saf; 2006; 29(9):735-68. PubMed ID: 16944962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semantic categories and relations for modelling adverse drug reactions towards a categorial structure for pharmacovigilance.
    Bousquet C; Trombert B; Kumar A; Rodrigues JM
    AMIA Annu Symp Proc; 2008 Nov; 2008():61-5. PubMed ID: 18998982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of measures of disproportionality in pharmacovigilance: three Dutch examples.
    Egberts AC; Meyboom RH; van Puijenbroek EP
    Drug Saf; 2002; 25(6):453-8. PubMed ID: 12071783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Physician attitudes toward the reporting of adverse drug reactions on the Pomeranian region].
    Schetz D; Sein Anand J
    Przegl Lek; 2015; 72(9):475-8. PubMed ID: 26827571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.
    Karlsson SA; Jacobsson I; Boman MD; Hakkarainen KM; Lövborg H; Hägg S; Jönsson AK
    Eur J Clin Pharmacol; 2015 May; 71(5):631-6. PubMed ID: 25845655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
    Rehan HS; Sah R; Gupta A; Nagar P
    Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug's safety profile.
    Motola D; Melis M; Lo Bianco S; Buccellato E; Biagi C; Vaccheri A
    Expert Opin Drug Saf; 2014 Jul; 13(7):867-73. PubMed ID: 24809453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reports.
    Mendes D; Alves C; Batel Marques F
    J Nurs Manag; 2014 Apr; 22(3):322-30. PubMed ID: 24754750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits].
    Durrieu G; Jacquot J; Baudrin D; Mège M; Rousseau V; Bagheri H; Bondon-Guitton E; Abadie D; Montastruc F; Bismuth M; Oustric S; Montastruc JL
    Therapie; 2017 Jun; 72(3):351-355. PubMed ID: 27865436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.